Takeda Executive Rejig In ICMEA Region As Shire Integration Shapes
Executive Summary
Takeda has shuffled certain key executive positions in the ICMEA (India, CIS, the Middle East and Africa) region where it hopes to sharpen its focus, while also emerging more agile as the integration with Shire advances.
You may also be interested in...
Takeda Gets New India Chief, Mandate To Broaden Access
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
Takeda Brings Rare Disease Drugs To India But Access Questions Linger
Takeda has introduced rare disease therapies from Shire’s portfolio in India and appears to be shifting gears in a market where it has long adopted a measured approach. But pricing and access to these products pose challenges that the Japanese multinational will need to address.
Takeda Says Last Pre-Shire Quarter ‘Robust’, But Quiet On Divestments
Takeda saw continued growth for mainstay drugs in what it described as a ‘robust’ last quarter of reporting before the inclusion of Shire, with global blockbuster Entyvio leading the way, but gave away little new on widely anticipated post-deal divestments.